STAT3 and malaria: Given the persistent activation of STAT3 and the emergence of hypoglycemia during treatment, it is highly important to investigate whether co-administration of ruxolitinib with anti-malarial drugs could improve survival in Plasmodium-infected mice and malaria patients.